Silo Pharma, Inc. (SILO) · Oct 14, 2026 · Acquisition
Software/IP acquisition
Silo Pharma’s acquisition transfers software and related intellectual property for stock, but the filing gives no asset detail or purchase-price amount.
Silo Pharma is a development-stage biotech building a pipeline of psychedelic and conventional therapies while also diversifying into AI and software assets; recent filings show the company has already pursued software acquisitions alongside its drug programs. This extends an existing diversification strategy, rather than changing the core biotech story. The agreement transfers software and all related intellectual property to Silo, including commercialization, licensing, derivative-work, and infringement-claim rights. 〔0〕 The direction was therefore partly known from Silo’s prior software deals, but the filing does not identify what the software does, how it will generate revenue, or how it fits with the company’s existing AI subsidiary. The key economic terms are too opaque to establish value. Item 3.02 indicates an equity issuance, and the agreement says Silo will issue a certificate or book-entry confirmation as the purchase price, but the provided filing content does not state the number of shares, implied valuation, or exact software assets. That prevents a meaningful assessment of dilution versus what Silo received. Execution is contractually protected, but not yet commercially validated. The seller must deliver a usable, unencrypted copy of the source and object code, while providing broad ownership warranties and indemnification for infringement or misconduct. 〔1〕 Those provisions reduce transfer and ownership risk, but they do not demonstrate adoption, revenue, or technical usefulness. Bottom line: This is another step toward Silo’s software diversification, but it is strategically additive rather than transformative. With the asset description, share count, and valuation undisclosed in the provided filing, the business impact remains unquantifiable for now.
Delivery of source code within three days of payment
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!